OBJECTIVE： To investigate the current situation of anticoagulant therapy for patients with non-valvular atrial fibrillation， and to provide reference for standardized anticoagulant therapy. METHODS： A total of 1 056 patients with non-valvular atrial fibrillation were collected from our hospital during Jul. 2015-Jun. 2016. According to 2012 European Society of Cardiology Guidelines for the Management of Atrial Fibrillation， the risks of thrombosis and hemorrhage were evaluated， and the standardized anticoagulant therapy was also evaluated. RESULTS： Among 1 056 patients with non-valvular atrial fibrillation， the number of patients with thrombosis risk score ≥1 was 1 028， accounting for 97.3％. 763 patients received antithrombosis therapy， and only 139 patients were given warfarin anticoagulant therapy. The international normalized ratio （INR） of prothrombin time in just 30.9％ of patients receiving warfarin was in line with the standard before discharge. CONCLUSIONS： The anticoagulant therapy for patients with non-valvular atrial fibrillation is still not optimistic， and effective measure should be adopted to improve the standardization of anticoagulant therapy in the patients with atrial fibrillation.